Yves Sciama is a freelance science writer, trained in biology and science journalism, who covers life and environmental sciences. His work has appeared in Science et Vie, Le Monde and other major French-language media, as well as in Science. He has won multiple prizes and fellowships, including a yearlong Knight Science Journalism Fellowship at the Massachusetts Institute of Technology in 2014, and is former president of AJSPI, the French association of science journalists.
Yves Sciama
Contributing writer
From this contributor
At the end of the earth with Paul-Antoine Libourel
The French researcher’s accomplishments working with chinstrap penguins in the Antarctic highlight the importance of recording sleep in the wild.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.